Pregled bibliografske jedinice broj: 1192385
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it? // British journal of clinical pharmacology, 88 (2022), 7; 3539-3541 doi:10.1111/bcp.15283 (međunarodna recenzija, pismo uredniku, znanstveni)
CROSBI ID: 1192385 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?
Autori
Trkulja, Vladimir
Izvornik
British journal of clinical pharmacology (0306-5251) 88
(2022), 7;
3539-3541
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, znanstveni
Ključne riječi
COVID-19 ; tocilizumab ; mortality
Sažetak
Meta-analysis of tocilizumab trials to assess effect on mortality - and suggested GRADE level.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
